Diana A. Fernandes holds a MSc Degree in Biological Engineering by Instituto Su­perior Técnico, University of Lisbon, 2015. She joined Hovione in the same year as an Industrial PhD Candidate in collaboration with Faculty of Pharmacy, Uni­versity of Lisbon, specializing in spray dried composite formulations for dry pow­der inhaler delivery of biopharmaceuticals, namely enzymes. Since 2018, Diana has also been working as an Inhaled Biopharmaceutical Formulation Scientist at Hovione R&D Drug Product Development Department, supporting the develop­ment and tech-transfer of Spray Drying and Jet Milling projects of inhalable clini­cal products ranging from small to large molecules, from lab to industrial scales.

She was one of the recipients of the prize for Women in Science at the 22nd Congress of the International Society for Aerosols in Medicine (ISAM), Montreux, Switzerland this year

Prof. Dr. Sven Stegemann is professor of patient-centric drug design and manu­facturing at the Graz University of Technology, Austria. Sven has worked over the course of 22 years for Capsugel, acting as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients. In his academic role, Sven focusses his research on the rational development of patient-centric drug products and their associated manufacturing technologies, as well as education and training of students and young scientists. He is the founder and chair of the AAPS focus group on patient-centric drug development, product design and manufacturing as well as the founder and president of the Geriatric Medicine Society e.V. He recently started the industrial-academic collab­oration partnership Patient Centric Medicine (PaCeMe) to suitable and meaning­ful guidance for patient-centric drug product design. He is the editor of the book “Developing Drug Products in an Aging Society: From Concept to Prescribing”, a multidisciplinary approach towards patient-centric drug development for the older and multimorbid patient populations.

Mark is responsible for the Health Solutions within Digital Health at TEVA Pharmaceuticals. Over ten years with TEVA and prior to that, sixteen with AstraZeneca. Mark has held various positions, including R&D Project Leader, VP Sales & Marketing, Strategic Planning & Business Development, and Global Brand Lead. He graduated in Aeronautical Sciences and completed his MBA at Durham University, UK.

During his career, he has led technology & especially inhaler development teams through engineering, CMC characterization, clinical evidence generation, registration within the US, EU, and International Markets, and ultimately, to successful global launch. Total Brand Leadership value >$2.5bn. Mark has numerous patents granted and pending in electronic communications, sports technologies, inhaled pharmaceutical development, and respiratory physiological function & predictive AI. Mark is the inventor of Digihaler®. The first FDA-approved digital inhaler with built-in sensors.

Dr. Orest Lastow is the CTO of Iconovo AB. He is also the co-founder, former CEO of Iconovo. He is responsible for the development of Iconovo’s inhalation platforms. He is also the founder and previous CEO of the Medicon Valley Inhalation Consortium, MVIC AB. Orest was with AstraZeneca for over 15 years and is the principal inventor of AstraZeneca’s new dry powder inhalation platform. He is the author of a textbook on atomization, many journal publications, book contributions, and patent applications.